GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Unicycive Therapeutics Inc (NAS:UNCY) » Definitions » PB Ratio

Unicycive Therapeutics (Unicycive Therapeutics) PB Ratio : (As of May. 05, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Unicycive Therapeutics PB Ratio?

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2024-05-05), Unicycive Therapeutics's share price is $1.12. Unicycive Therapeutics's Book Value per Share for the quarter that ended in Dec. 2023 was $-0.11. Hence, Unicycive Therapeutics's PB Ratio of today is .

The historical rank and industry rank for Unicycive Therapeutics's PB Ratio or its related term are showing as below:

During the past 5 years, Unicycive Therapeutics's highest PB Ratio was 8.88. The lowest was 1.76. And the median was 2.51.

UNCY's PB Ratio is not ranked *
in the Biotechnology industry.
Industry Median: 2.5
* Ranked among companies with meaningful PB Ratio only.

During the past 3 years, the average Book Value Per Share Growth Rate was 21.50% per year.

During the past 5 years, the highest 3-Year average Book Value Per Share Growth Rate of Unicycive Therapeutics was 21.50% per year. The lowest was 20.20% per year. And the median was 20.85% per year.

Back to Basics: PB Ratio


Unicycive Therapeutics PB Ratio Historical Data

The historical data trend for Unicycive Therapeutics's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Unicycive Therapeutics PB Ratio Chart

Unicycive Therapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
PB Ratio
- - 1.87 - -

Unicycive Therapeutics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - 8.78 -

Competitive Comparison of Unicycive Therapeutics's PB Ratio

For the Biotechnology subindustry, Unicycive Therapeutics's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Unicycive Therapeutics's PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Unicycive Therapeutics's PB Ratio distribution charts can be found below:

* The bar in red indicates where Unicycive Therapeutics's PB Ratio falls into.



Unicycive Therapeutics PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

Unicycive Therapeutics's PB Ratio for today is calculated as follows:

PB Ratio=Share Price/Book Value per Share (Q: Dec. 2023)
=1.12/-0.11
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.


Unicycive Therapeutics  (NAS:UNCY) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.


Unicycive Therapeutics PB Ratio Related Terms

Thank you for viewing the detailed overview of Unicycive Therapeutics's PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Unicycive Therapeutics (Unicycive Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
4300 El Camino Real, Suite 210, Los Altos, CA, USA, 94022
Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's lead drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury.
Executives
Sandeep Laumas director 8480 HONEYCUTT RD, SUITE 200, RALEIGH NC 27615
John L Ryan director C/O KADMON HOLDINGS, LLC, 450 E. 29TH STREET, NEW YORK NY 10016
Sara Kenkare-mitra director C/O ALECTOR, INC, 131 OYSTER POINT BLVD, SUITE 600, SOUTH SAN FRANCISCO CA 94080
Gaurav Aggarwal director C/O PANORAMA CAPITAL, 2440 SAND HILL ROAD, SUITE 302, MENLO PARK CA 94025
Douglas Jermasek other: EVP of Corporate Strategy 4300 EL CAMINO REAL, SUITE 210, LOS ALTOS CA 94022
Brigitte Schiller director UNICYCIVE THERAPEUTICS, INC., 5150 EL CAMINO REAL, SUITE A-32, LOS ALTOS CA 94022
John Townsend officer: Chief Financial Officer 15150 AVENUE OF SCIENCE, SUITE 200, SAN DIEGO CA 92128
Pramod Gupta officer: EVP, Pharmaceuticals and BD UNICYCIVE THERAPEUTICS, INC., 5150 EL CAMINO REAL, SUITE A-32, LOS ALTOS CA 94022
Shalabh K. Gupta director, officer: CEO UNICYCIVE THERAPEUTICS, INC., 5150 EL CAMINO REAL, SUITE A-32, LOS ALTOS CA 94022

Unicycive Therapeutics (Unicycive Therapeutics) Headlines